Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia expecially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments.
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Main text Introduction
Alemtuzumab (Lemtrada TM ) is a humanized monoclonal antibody that selectively targets the CD52
antigen, expressed mainly on T and B lymphocytes and, at lower levels, on natural killer, monocytes and dendritic cells 1,2 . In two phase 3 clinical trials (Comparison of Alemtuzumab and
Rebif Efficacy in Multiple Sclerosis -CARE-MS I and CARE-MS II) 3, 4 in relapsing remitting multiple sclerosis (RRMS) patients, alemtuzumab resulted more effective than interferon beta-1a
(IFN beta-1a) in reducing relapses and brain volume loss. Alemtuzumab induces a profound and prolonged lymphopenia especially of the CD4+ population 5 . The depletion of CD4+ cells usually lasts for years, but an accelerated CD4+ recovery was associated with an early return of disease activity 5 .
Cases
Here we report the atypical immunological features of two RRMS patients who presented a sustained disease activity despite alemtuzumab treatment. These patients belong to the cohort of 29 alemtuzumab treated patients from CARE-MS I and CARE-MS II trials of our previous 6 and ongoing studies 7 . Patients were neurologically evaluated at baseline and then every 6 months or in case of relapses. Immunological studies were performed at baseline and every 6 months during the first 24 months and every 12 months thereafter. 
Discussion
One of the main challenges in the research on MS is the identification of biomarkers detectable in the biological fluids, especially blood, that could easily identify the response to therapy and guide patient management reliably. In this context, lymphocytes count and their immunological profile seems to act as response predictors to second line drugs in which risks and benefits should be carefully balanced: recently, it was observed that lymphocytes subpopulation evaluation might predict the risk of clinical and radiological activities in fingolimod treated patients 9 and that lymphocytosis could be a biomarker of therapeutic efficacy in natalizumab treated patients 10 .
Cossburn et al. 5 reported, in 56 RRMS alemtuzumab treated patients followed for a median of 39.5
months, that relapse-free patients had a significant lower CD4+ lymphocyte count from 6 months ACCEPTED MANUSCRIPT
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after treatment until the end of the study period compared to patients with one or more relapses.
Similarly, our case report on the long lasting behaviour of the CD4+ T cells subset in alemtuzumab treated patients shows two patients (followed for 5 and 7.5 years from starting alemtuzumab) with almost unchanged T CD4+ percentage from baseline despite the repeated alemtuzumab administrations needed for clinical and radiological relapses. In our study cohort 6,7 alemtuzumab administration strongly affected the percentage of CD4+ cells: it was reduced by 66% at Month 6
and by 51% at Month 12 and then slowly increased returning to baseline around Month 48 ( Figure   1 ). By contrast, the CD4+ population of these 2 patients seems not affected by alemtuzumab. The CD52 different expression in CD4+ T cell 11 might explain why some patients do not show a CD4+
T cell decrease after alemtuzumab. In addition, the CD4+ T cell percentage was below LNL already before alemtuzumab in those two patients. It could be possible that they had CD4+ T cells already suppressed by preceding treatment with IFN beta-1a; one of the effects of IFNβ is indeed the impairment of lymphocytes egression from the lymphnodes 12 ; CD4+ T cells could remain concealed from the usual therapeutic effects of alemtuzuamb as it was hypothesized in patients who developed unexpected disease activity during alemtuzuamb treatment after fingolimod discontinuation 13 . These patients might so require a treatment with a drug that preferentially affects B rather than T cells, or a better strategy for the therapeutic switch. Based on the small sample size, definitive conclusions cannot be drawn and further analyses are needed . If our results will be confirmed in an higher number of patients, the evaluation of the CD4+ T cells percentage, before and after alemtuzumab treatment, could become a helpful tool to predict clinical response to the drug, in order to better address the therapeutic choice.
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